Spots Global Cancer Trial Database for transitional cell carcinoma
Every month we try and update this database with for transitional cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial | NCT02160600 | Renal Cell Carc... Renal Cysts Transitional Ce... AML | Standard multip... split bolus Dua... | 18 Years - | All India Institute of Medical Sciences, New Delhi | |
| Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel | NCT01668459 | Transitional Ce... | Cabazitaxel Best Supportive... | 18 Years - | University Hospital Birmingham NHS Foundation Trust | |
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | NCT04179110 | Transitional Ce... | Pembrolizumab a... | 18 Years - | Yale University | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Relationship of Ochratoxin A to Upper Urologic Cancers | NCT00216801 | Transitional Ce... Renal Cell Canc... Testicular Canc... | 18 Years - | Lawson Health Research Institute | ||
| Relationship of Ochratoxin A to Upper Urologic Cancers | NCT00216801 | Transitional Ce... Renal Cell Canc... Testicular Canc... | 18 Years - | Lawson Health Research Institute | ||
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | NCT02426125 | Urothelial Carc... | Ramucirumab Docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer | NCT02581982 | Transitional Ce... | Laboratory Biom... Paclitaxel Pembrolizumab | 18 Years - | Wake Forest University Health Sciences | |
| Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT | NCT02471547 | Transitional Ce... | BWT with Mitomy... | 18 Years - | Sheba Medical Center | |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | NCT00389155 | Bladder Cancer Transitional Ce... Metastasis | Vinflunine Gemcitabine Placebo | 18 Years - | Bristol-Myers Squibb | |
| First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | NCT00389155 | Bladder Cancer Transitional Ce... Metastasis | Vinflunine Gemcitabine Placebo | 18 Years - | Bristol-Myers Squibb | |
| A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy | NCT00714025 | Transitional Ce... | RAD001 | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer | NCT00696007 | Transitional Ce... | Gemcitabine and... Retrospective c... | 18 Years - | Lahey Clinic | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| Single Agent Abraxane as Second Line Therapy in Bladder Cancer | NCT00683059 | Transitional Ce... | Paclitaxel | 18 Years - | Sunnybrook Health Sciences Centre | |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | NCT05052372 | Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad... | Balversa | 18 Years - | xCures | |
| Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging | NCT00612326 | Bladder Cancer Transitional Ce... | MRI and PET sca... | - | Memorial Sloan Kettering Cancer Center | |
| Single Agent Abraxane as Second Line Therapy in Bladder Cancer | NCT00683059 | Transitional Ce... | Paclitaxel | 18 Years - | Sunnybrook Health Sciences Centre | |
| Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging | NCT00612326 | Bladder Cancer Transitional Ce... | MRI and PET sca... | - | Memorial Sloan Kettering Cancer Center | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas | NCT00070070 | Transitional Ce... | TICE®-strain BC... NY-ESO-1 protei... sargramostim | 18 Years - | Ludwig Institute for Cancer Research | |
| Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma | NCT02326909 | Transitional Ce... | Optical Coheren... Optical Coheren... | 18 Years - | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
| Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor | NCT04179110 | Transitional Ce... | Pembrolizumab a... | 18 Years - | Yale University | |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin | NCT01599013 | Bladder Transit... | Vinflunine, Gem... Vinflunine, Car... | 18 Years - 79 Years | Pierre Fabre Medicament | |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | NCT01215136 | Transitional Ce... Bladder Carcino... Urothelial Carc... | Everolimus Everolimus Paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | NCT05052372 | Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad... | Balversa | 18 Years - | xCures | |
| Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder | NCT04878250 | Transitional Ce... Bladder Cancer | Bintrafusp alfa | 18 Years - | Queen Mary University of London | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | NCT02834013 | Acinar Cell Car... Adenoid Cystic ... Adrenal Cortica... Adrenal Gland P... Anal Canal Neur... Anal Canal Undi... Angiosarcoma Apocrine Neopla... Appendix Mucino... Bartholin Gland... Basal Cell Carc... Bladder Adenoca... Breast Metaplas... Cervical Adenoc... Cholangiocarcin... Chordoma Colorectal Squa... Desmoid Fibroma... Endometrial Tra... Endometrioid Ad... Esophageal Neur... Esophageal Undi... Extrahepatic Bi... Extramammary Pa... Fallopian Tube ... Fallopian Tube ... Fibromyxoid Tum... Gallbladder Car... Gastric Neuroen... Gastric Squamou... Gastric Undiffe... Gastrointestina... Gestational Tro... Giant Cell Carc... Human Papilloma... Intestinal Neur... Intrahepatic Ch... Lung Neuroendoc... Lung Sarcomatoi... Major Salivary ... Malignant Odont... Malignant Perip... Malignant Solid... Malignant Testi... Metastatic Mali... Metastatic Pitu... Minimally Invas... Mixed Mesoderma... Mucinous Adenoc... Mucinous Cystad... Nasal Cavity Ad... Nasal Cavity Ca... Nasopharyngeal ... Nasopharyngeal ... Nasopharyngeal ... Oral Cavity Car... Oropharyngeal U... Ovarian Adenoca... Ovarian Germ Ce... Ovarian Mucinou... Ovarian Squamou... Ovarian Transit... Pancreatic Acin... Pancreatic Neur... Paraganglioma Paranasal Sinus... Paranasal Sinus... Parathyroid Gla... PEComa Penile Squamous... Peritoneal Meso... Placental Chori... Primary Periton... Pseudomyxoma Pe... Rare Disorder Scrotal Squamou... Seminal Vesicle... Seminoma Serous Cystaden... Small Intestina... Small Intestina... Spindle Cell Ne... Teratoma With S... Testicular Non-... Thyroid Gland C... Tracheal Carcin... Transitional Ce... Ureter Adenocar... Ureter Squamous... Urethral Adenoc... Urethral Squamo... Vaginal Adenoca... Vaginal Squamou... Vulvar Carcinom... | Biospecimen Col... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas | NCT00070070 | Transitional Ce... | TICE®-strain BC... NY-ESO-1 protei... sargramostim | 18 Years - | Ludwig Institute for Cancer Research | |
| First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | NCT01215136 | Transitional Ce... Bladder Carcino... Urothelial Carc... | Everolimus Everolimus Paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma | NCT03296306 | Bladder Cancer Ureter Cancer Urethral Cancer Transitional Ce... | Treatment durat... | 18 Years - | Asan Medical Center | |
| Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy | NCT03193788 | Bladder Cancer Ureter Cancer Transitional Ce... | pemetrexed Folic Acid Vitamin B12 Inj... Dexamethasone | 20 Years - | Asan Medical Center | |
| Bristol Bladder Trial | NCT01616875 | Infiltrating Bl... | Cabazitaxel + C... | 18 Years - | University Hospitals Bristol and Weston NHS Foundation Trust | |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | NCT03896958 | Cancer, All Typ... Cancer of Liver Cancer of Stoma... Cancer of Head ... Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Colon Cancer Skin Cancer of Cervi... Cancer, Metasta... Cancer of Laryn... Cancer of Neck Cancer of Lung Cancer of Brain... Cancer of Vulva... Cancer of Pancr... Sarcoma GIST Small-cell Lung... Adenocarcinoma ... Cancer of Prost... Cancer, Advance... Adrenal Cancer Testicular Canc... Uterine Cancer Bronchoalveolar... Cancer Unknown ... Glioblastoma Mu... Oligodendroglio... Breast Cancer Renal Cell Carc... Hepatocellular ... Cholangiocarcin... Squamous Cell C... Transitional Ce... Cancer, Other Cancer, Anal Melanoma Cancer, Bile Du... Cancer, Bladder Cancer Cords Vo... Cancers Cell Ne... Cancer Differen... Cancer, Anaplas... | 1 Month - 99 Years | SpeciCare | ||
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | NCT01454089 | Urologic Neopla... Metastatic Blad... Urinary Tract N... | OGX-427 600 mg OGX-427 1000 mg Placebo Gemcitabine Cisplatin Carboplatin | 18 Years - | Achieve Life Sciences | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma | NCT03296306 | Bladder Cancer Ureter Cancer Urethral Cancer Transitional Ce... | Treatment durat... | 18 Years - | Asan Medical Center | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | NCT00101608 | Transitional Ce... Bladder Neoplas... Kidney Neoplasm... Ureter Neoplasm... Bladder Cancer Neoplasm, Bladd... | vinflunine | 18 Years - | Bristol-Myers Squibb | |
| Alisertib in Chemotherapy-pretreated Urothelial Cancer | NCT02109328 | Bladder Cancer Transitional Ce... | Alisertib Paclitaxel Placebo | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) | NCT03896958 | Cancer, All Typ... Cancer of Liver Cancer of Stoma... Cancer of Head ... Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Colon Cancer Skin Cancer of Cervi... Cancer, Metasta... Cancer of Laryn... Cancer of Neck Cancer of Lung Cancer of Brain... Cancer of Vulva... Cancer of Pancr... Sarcoma GIST Small-cell Lung... Adenocarcinoma ... Cancer of Prost... Cancer, Advance... Adrenal Cancer Testicular Canc... Uterine Cancer Bronchoalveolar... Cancer Unknown ... Glioblastoma Mu... Oligodendroglio... Breast Cancer Renal Cell Carc... Hepatocellular ... Cholangiocarcin... Squamous Cell C... Transitional Ce... Cancer, Other Cancer, Anal Melanoma Cancer, Bile Du... Cancer, Bladder Cancer Cords Vo... Cancers Cell Ne... Cancer Differen... Cancer, Anaplas... | 1 Month - 99 Years | SpeciCare | ||
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center | |
| Weekly TP-HDFL in the Treatment of Advanced TCC | NCT00154687 | Transitional Ce... | Paclitaxel, Cis... | 18 Years - | National Taiwan University Hospital | |
| A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen | NCT00623831 | Melanoma Sarcoma Gastrointestina... Head and Neck C... Transitional Ce... Prostate Cancer Ovarian Carcino... Esophageal Canc... Breast Cancer | Mixed bacterial... | 18 Years - | Ludwig Institute for Cancer Research | |
| CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood | NCT04811846 | Urinary Bladder... Transitional Ce... Urogenital Neop... Circulating Tum... Neoplasms | Bipolar transur... Bipolar transur... | 18 Years - | University Teaching Hospital Hall in Tirol | |
| Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer | NCT01395225 | Bladder Cancer Transitional Ce... | 18 Years - | University of British Columbia | ||
| Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder | NCT02662309 | Bladder Cancer | MPDL3280A | 18 Years - | Queen Mary University of London | |
| Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors | NCT00567684 | Bladder Cancer | Computed Tomogr... Intravenous Uro... | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | NCT00722553 | Carcinoma, Tran... Bladder Cancer Bladder Neoplas... | Pralatrexate In... Vitamin B12 Folic Acid | 18 Years - | Acrotech Biopharma Inc. | |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer | NCT02426125 | Urothelial Carc... | Ramucirumab Docetaxel Placebo | 18 Years - | Eli Lilly and Company | |
| Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder Cancer | NCT00393809 | Bladder Neoplas... | DTA-H19 | 18 Years - | Hebrew University of Jerusalem | |
| Efficacy and Safety of UGN-101 in Recurrent Patients | NCT04006691 | Carcinoma Transitional Ce... Transitional Ce... | UGN-101 instill... | 18 Years - | UroGen Pharma Ltd. | |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer | NCT02300610 | Bladder Cancer Carcinoma, Tran... Renal Pelvis Ca... Ureter Cancer Urethra Cancer | Enzalutamide Cisplatin Gemcitabine | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer | NCT01395225 | Bladder Cancer Transitional Ce... | 18 Years - | University of British Columbia | ||
| Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC | NCT00173862 | Transitional Ce... | Gemcitabine, If... | 18 Years - | National Taiwan University Hospital | |
| Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | NCT03238664 | Infiltrating Bl... Stage II Bladde... Transitional Ce... | Biopsy High-Intensity ... Laboratory Biom... Radical Cystect... Ultrasonography | 18 Years - | University of Southern California | |
| Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma | NCT02887248 | Urothelial Carc... Bladder Cancer Transitional Ce... | nab-paclitaxel Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | NCT03238664 | Infiltrating Bl... Stage II Bladde... Transitional Ce... | Biopsy High-Intensity ... Laboratory Biom... Radical Cystect... Ultrasonography | 18 Years - | University of Southern California | |
| Detecting Transitional Cell Carcinoma From Haematuria | NCT03256877 | Transitional Ce... | 18 Years - | Hull University Teaching Hospitals NHS Trust | ||
| Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | NCT02420847 | Metastatic Urot... Transitional Ce... Unresectable Tr... | Doxorubicin Hyd... Gemcitabine Hyd... Ixazomib Citrat... | 18 Years - | M.D. Anderson Cancer Center | |
| Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | NCT03927573 | Non-small Cell ... Prostate Cancer Renal Cancer Transitional Ce... | GEM3PSCA | 18 Years - | AvenCell Europe GmbH | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer | NCT00479089 | Bladder Cancer | Docetaxel ZD1839 Dexamethasone | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
